Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Public Library of Science Country of Publication: United States NLM ID: 101291488 Publication Model: eCollection Cited Medium: Internet ISSN: 1935-2735 (Electronic) Linking ISSN: 19352727 NLM ISO Abbreviation: PLoS Negl Trop Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: San Francisco, CA : Public Library of Science
    • Subject Terms:
    • Abstract:
      Onchocerca volvulus is the nematode pathogen responsible for human onchocerciasis also known as "River blindness", a neglected tropical disease that affects up to 18 million people worldwide. Helminths Excretory Secretory Products (ESPs) constitute a rich repertoire of molecules that can be exploited for host-parasite relationship, diagnosis and vaccine studies. Here, we report, using a range of molecular techniques including PCR, western blot, recombinant DNA technology, ELISA, high performance thin-layer chromatography and mass spectrometry that the 28 KDa cysteine-rich protein (Ov28CRP) is a reliable component of the O. volvulus ESPs to address the biology of this parasite. We showed that (1) Ov28CRP is a putative ganglioside GM2 Activator Protein (GM2AP) conserved in nematode; (2) OvGM2AP gene is transcriptionally activated in all investigated stages of the parasitic life cycle, including larval and adult stages; (3) The full-length OvGM2AP was detected in in-vitro O. volvulus ESPs of adult and larval stages; (4) the mass expressed and purified recombinant OvGM2AP purified from insect cell culture medium was found to be glycosylated at asparagine 173 and lacked N-terminal signal peptide sequence; (5) the recombinant OvGM2AP discriminated serum samples of infected and uninfected individuals; (6) OvGM2AP competitively inhibits MUG degradation by recombinant β-hexosaminidase A but not MUGS, and could not hydrolyze the GM2 to GM3; (7) humoral immune responses to the recombinant OvGM2AP revealed a negative correlation with ivermectin treatment. Altogether, our findings suggest for the first time that OvGM2AP is an antigenic molecule whose biochemical and immunological features are important to gain more insight into our understanding of host-parasite relationship, as well as its function in parasite development at large.
      Competing Interests: The authors have declared no competing interests exist.
    • References:
      Int J Parasitol. 2013 Mar;43(3-4):301-10. (PMID: 23291463)
      Trop Med Parasitol. 1985 Mar;36(1):12-6. (PMID: 4001765)
      PLoS Negl Trop Dis. 2016 Mar 11;10(3):e0004492. (PMID: 26967331)
      PLoS One. 2018 Sep 26;13(9):e0202915. (PMID: 30256790)
      Mol Immunol. 2007 May;44(12):3211-21. (PMID: 17346796)
      J Biol Chem. 1997 Jan 31;272(5):2828-33. (PMID: 9006924)
      Protein Expr Purif. 2003 Feb;27(2):259-66. (PMID: 12597885)
      Parasitol Res. 2013 Sep;112(9):3335-46. (PMID: 23820606)
      Mol Biochem Parasitol. 2006 Jun;147(2):224-9. (PMID: 16569450)
      Infect Genet Evol. 2011 Jun;11(4):778-83. (PMID: 20713183)
      FEBS Lett. 2010 May 3;584(9):1700-12. (PMID: 19836391)
      Science. 2009 Apr 17;324(5925):384-7. (PMID: 19325080)
      Acta Trop. 2015 Feb;142:156-66. (PMID: 25479441)
      Clin Pharmacol Drug Dev. 2012 Jan;1(1):32-7. (PMID: 27206144)
      FEBS Lett. 1996 Dec 16;399(3):227-31. (PMID: 8985151)
      Nat Protoc. 2015 Jun;10(6):845-58. (PMID: 25950237)
      Biochem Cell Biol. 2004 Feb;82(1):225-53. (PMID: 15052340)
      Semin Immunopathol. 2012 Nov;34(6):847-61. (PMID: 23053393)
      FEBS J. 2006 Mar;273(5):982-91. (PMID: 16478472)
      Trop Med Parasitol. 1988 Dec;39 Suppl 4:418-21. (PMID: 3227242)
      J Lipid Res. 2015 Sep;56(9):1747-61. (PMID: 26175473)
      Int J Parasitol. 2013 Mar;43(3-4):293-9. (PMID: 23291459)
      J Mol Biol. 2000 Dec 1;304(3):411-22. (PMID: 11090283)
      Microbes Infect. 2007 Apr;9(4):498-506. (PMID: 17347015)
      Int Health. 2018 Mar 1;10(suppl_1):i20-i26. (PMID: 29471336)
      Biophys J. 2009 Jul 8;97(1):257-66. (PMID: 19580763)
      Hybridoma (Larchmt). 2005 Dec;24(6):283-90. (PMID: 16332194)
      Nat Rev Immunol. 2003 Sep;3(9):733-44. (PMID: 12949497)
      Mol Endocrinol. 2005 Dec;19(12):3097-106. (PMID: 16081518)
      Annu Rev Pathol. 2006;1:497-536. (PMID: 18039124)
      Trans R Soc Trop Med Hyg. 2002 Sep-Oct;96(5):541-2. (PMID: 12474485)
      Wkly Epidemiol Rec. 2015 Oct 23;90(43):577-81. (PMID: 26495516)
      BMC Infect Dis. 2018 May 2;18(1):200. (PMID: 29716541)
      mBio. 2016 Nov 23;7(6):. (PMID: 27881553)
      Trop Med Parasitol. 1988 Dec;39 Suppl 4:423-40. (PMID: 2852394)
      Clin Infect Dis. 2014 Oct;59(7):923-32. (PMID: 24944228)
      Mol Biochem Parasitol. 2005 Aug;142(2):193-202. (PMID: 15885823)
      Anal Biochem. 2009 Feb 15;385(2):383-5. (PMID: 19061853)
      Mol Ther Methods Clin Dev. 2016 Mar 02;3:15057. (PMID: 26966698)
      Antimicrob Agents Chemother. 2011 Nov;55(11):5200-4. (PMID: 21896908)
      Methods Enzymol. 1987;138:319-41. (PMID: 3600331)
      Biochim Biophys Acta. 1998 Jul 31;1393(1):1-18. (PMID: 9714704)
      Lancet. 2018 Oct 6;392(10154):1170-1172. (PMID: 29361336)
      J Mol Biol. 2003 Aug 22;331(4):951-64. (PMID: 12909021)
      Sci Rep. 2019 Mar 13;9(1):4409. (PMID: 30867498)
      Parasit Vectors. 2017 Aug 3;10(1):373. (PMID: 28774318)
      Traffic. 2006 Mar;7(3):365-77. (PMID: 16497229)
      Mol Biochem Parasitol. 2008 Apr;158(2):101-11. (PMID: 18215431)
      Ann Trop Med Parasitol. 2010 Sep;104(6):455-64. (PMID: 20863434)
      Parasitol Res. 1991;77(6):526-35. (PMID: 1924261)
      Parasite Immunol. 2017 May;39(5):. (PMID: 28066896)
      Biochim Biophys Acta. 1991 Jan 30;1061(2):297-303. (PMID: 1998698)
      J Infect Dis. 2000 Dec;182(6):1796-9. (PMID: 11069258)
      Biochem J. 1993 Jun 1;292 ( Pt 2):571-6. (PMID: 8503891)
      Infect Dis Poverty. 2018 Apr 6;7(1):30. (PMID: 29628019)
      Trends Parasitol. 2018 Jan;34(1):64-79. (PMID: 28958602)
      EJIFCC. 2009 Jan 20;19(4):203-11. (PMID: 27683318)
      Mol Pharmacol. 2009 Mar;75(3):437-46. (PMID: 19064628)
      Mol Cell Proteomics. 2007 Dec;6(12):2100-9. (PMID: 17761667)
      Nat Cell Biol. 2008 Oct;10(10):1146-53. (PMID: 18776900)
      Biochemistry. 1997 Jul 8;36(27):8325-31. (PMID: 9204879)
      Filaria J. 2003 Oct 24;2 Suppl 1:S7. (PMID: 14975064)
      Biometrics. 1988 Sep;44(3):837-45. (PMID: 3203132)
      Int J Parasitol Drugs Drug Resist. 2012 Apr 14;2:134-53. (PMID: 24533275)
      J Biol Chem. 1991 Jan 25;266(3):1879-87. (PMID: 1824846)
      J Clin Pharmacol. 2003 Oct;43(10):1108-15. (PMID: 14517193)
      J Parasitol. 2010 Feb;96(1):219-21. (PMID: 19803543)
      Am J Trop Med Hyg. 2012 Jan;86(1):122-125. (PMID: 22232462)
      Nucleic Acids Res. 2008 Apr;36(7):2295-300. (PMID: 18287115)
      Nat Microbiol. 2016 Nov 21;2:16216. (PMID: 27869790)
      Hoppe Seylers Z Physiol Chem. 1979 Dec;360(12):1837-49. (PMID: 527942)
      Mol Cell Proteomics. 2015 Dec;14(12):3224-33. (PMID: 26472727)
    • Accession Number:
      0 (DNA, Helminth)
      0 (G(M2) Activator Protein)
      0 (Helminth Proteins)
      0 (Immunoglobulin G)
      0 (Recombinant Proteins)
    • Publication Date:
      Date Created: 20190723 Date Completed: 20191223 Latest Revision: 20231013
    • Publication Date:
      20240105
    • Accession Number:
      PMC6675134
    • Accession Number:
      10.1371/journal.pntd.0007591
    • Accession Number:
      31329585